Megan Clark Buys 200 Shares of CSL Limited (ASX:CSL) Stock

CSL Limited (ASX:CSL) insider Megan Clark bought 200 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of A$250.06 ($159.27) per share, for a total transaction of A$50,012.00 ($31,854.78).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark purchased 132 shares of CSL stock. The stock was bought at an average price of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Stock Performance

The company has a market capitalization of $77.43 billion, a PE ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.

CSL Increases Dividend

The company also recently declared a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be paid a $2.073 dividend. The ex-dividend date of this dividend is Sunday, March 9th. This represents a yield of 0.81%. This is a boost from CSL’s previous Interim dividend of $1.83. CSL’s dividend payout ratio (DPR) is currently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.